Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why OncoSec Medical Shares Are Soaring Today

OncoSec Medical Inc (NASDAQ: ONCS) shares are trading higher Monday after the company announced it's seeking withdrawal of its registration statement.
byAdam Eckert
April 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

OncoSec Medical Inc (NASDAQ:ONCS) shares are trading higher Monday after the company announced it’s seeking withdrawal of its registration statement.

What Happened: OncoSec Medical has submitted a request to the SEC to withdraw its registration statement that it filed on March 28. 

The March filing detailed an anticipated offering of more than 11 million shares and over 11 million warrants. 

“The Company is seeking withdrawal of the Registration Statement because it opted not to pursue the offering contemplated thereby,” the company said in the new filing. 

OncoSec confirmed that no securities were sold pursuant to the previously announced offering. 

OncoSec is a biotechnology company focused on developing intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. 

From Last Week: OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study

ONCS Price Action: OncoSec has a 52-week high of $25.74 and a 52-week low of 73 cents.

The stock was up 48.1% at $1.67 at time of publication, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

IM Cannabis’ Q4 Revenue: Gross Profit Drops Due To Negative Impact Of Israel-Hamas War, Sees Germany As Growth Opportunity

By Jelena Martinovic
March 28, 11:19 AM
IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) announced on Thursday its financial and operational results for the year ended Dec. 2023. The Toronto-headquartered medical cannabis company with a focus on Israel and Germany reported a 10% year-over-year decrease in revenue to CA$48.8 million ($36 million) in 2023. IM Cannabis attributed it to "negative currency fluctuations and the impact of the Israel-Hamas war on the company's operations." Fourth quarter revenue dropped 26% year-over-year to CA$10.7 million. "As previously warned and as expected, unfortunately, the Israel-Hamas war had a negative impact on our fourth quarter 2023 results, which weighed on our full-year results.," Uri Birenberg, chief financial officer of IMC, said. "Coupled with our fourth quarter of 2023 inventory reduction, the war caused our fourth quarter gross profit to decrease by 68% as compared to the fourth quarter of 2022."

CSE:IMCC